Integrated Population Pharmacokinetics of Daprodustat in Patients with Chronic Kidney Disease with Anemia
Clinical Pharmacokinetics · 2024
DOI: 10.1007/s40262-024-01417-9 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Clinical Pharmacokinetics, 2024. Verfasst von Kelly M Mahar und 4 weiteren Autor:innen. Beteiligte Einrichtung: GSK, Collegeville, PA, USA. kelly.m.mahar@gsk.com. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Anemia, Glycine, Models, Biological. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: GSK.
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVE: Daprodustat is a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) approved in the USA for treatment of anemia owing to chronic kidney disease (CKD) in dialysis-dependent adults and in Japan for treatment of CKD in dialysis- and non-dialysis dependent adults. This analysis characterized the population pharmacokinetics (PopPK) of daprodustat in adults with CKD and evaluated the influence of intrinsic and extrinsic factors. METHODS: This PopPK analysis included data from one phase 2B and four phase 3 studies comprising 707 CKD subjects dose titrated to prespecified target hemoglobin levels with daprodustat doses ranging from 1 to 24 mg once daily and 2 to 48 mg given three times a week (TIW). Model development leveraged a previous phase 1/2 PopPK model. Stepwise covariate analysis included 20 extrinsic and intrinsic factors. Model evaluation used standard goodness-of-fit and visual predictive checks. RESULTS: Daprodustat PopPK was adequately characterized using a three-compartment distribution model with first-order elimination. The absorption phase was described using five transit compartments. Oral clearance and volume of distribution was 24.6 L/h and 26.9 L, respectively. Body weight dependence (with fixed allometric coefficients) of clearance and volume terms was a statistically significant covariate. Concomitant use of clopidogrel (moderate CYP2C8 inhibitor) decreased oral clearance, resulting in higher area under the plasma concentration-time curve (AUC) ratio of 1.59 (90% CI: 1.39-1.82), subjects' dialysis status (non-dialysis versus dialysis) had an effect on absorption, with Cmax ratio of 1.19 (90% CI: 1.09-1.30). None of the other investigated intrinsic or extrinsic covariates, including concomitant administration with phosphate binders, oral iron and acid reducing agents resulted in a significant change in daprodustat systemic exposure. CONCLUSION: The PopPK of daprodustat in the CKD population with anemia was adequately characterized. Allometrically-scaled body weight on clearance and volume, dialysis status on absorption and clopidogrel on clearance were statistically significant covariates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- GSK, Collegeville, PA, USA. kelly.m.mahar@gsk.com.
- GSK, London, UK.
- Leiden Experts on Advanced Pharmacokinetics and Pharmacodynamics (LAP&P), Leiden, The Netherlands.
ORCID-Profile: Kelly M Mahar
Förderung
- GSK
Zitieren
APA
Mahar, K. M., Yang, S., Mesic, E., Post, T. M., & Goulooze, S. C. (2024). Integrated Population Pharmacokinetics of Daprodustat in Patients with Chronic Kidney Disease with Anemia. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-024-01417-9
Vancouver
Mahar KM, Yang S, Mesic E, Post TM, Goulooze SC. Integrated Population Pharmacokinetics of Daprodustat in Patients with Chronic Kidney Disease with Anemia. Clinical Pharmacokinetics. 2024. doi:10.1007/s40262-024-01417-9
BibTeX
@article{Mahar2024,
author = {Mahar, Kelly M and Yang, Shuying and Mesic, Emir and Post, Teun M and Goulooze, Sebastiaan C},
title = {Integrated Population Pharmacokinetics of Daprodustat in Patients with Chronic Kidney Disease with Anemia},
journal = {Clinical Pharmacokinetics},
year = {2024},
doi = {10.1007/s40262-024-01417-9}
}
EUVIMED